$Femasys (FEMY.US)$ Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach Thursday, 13th March at 8:30 am ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, anno...
$Femasys (FEMY.US)$ Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials Tuesday, 25th February at 9:20 am --Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners-- ATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unme...
$Femasys (FEMY.US)$ Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices Tuesday, 11th February at 9:00 am ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the Medicines & Healthcare products R...
$Femasys (FEMY.US)$ Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices Tuesday, 4th February at 9:00 am ATLANTA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the Israeli Medical Device Divisi...
$Femasys (FEMY.US)$ Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control Thursday, 30th January at 8:30 am ATLANTA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the European Patent Office ("EP...
$Femasys (FEMY.US)$Reuters just Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of Femaseed® for Female Infertility Treatment
$Femasys (FEMY.US)$Reuters· 4 mins ago Femasys Announces Partnership With Hrc Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer Femaseed
$Femasys (FEMY.US)$ Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
Report
No comment yet
Sign in to post a comment
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Femasys Stock Forum
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
Thursday, 13th March at 8:30 am
ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, anno...
Could This Non-Surgical Birth Control Method Replace Traditional Sterilization? Clinical Trials Say Yes
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
Tuesday, 25th February at 9:20 am
--Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners--
ATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unme...
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
Tuesday, 11th February at 9:00 am
ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the Medicines & Healthcare products R...
Femasys -Israeli Regulatory Approvals for Femaseed for Female Infertility Treatment and Two Diagnostic Devices
Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
Tuesday, 4th February at 9:00 am
ATLANTA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the Israeli Medical Device Divisi...
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
Thursday, 30th January at 8:30 am
ATLANTA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the European Patent Office ("EP...
just
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of Femaseed® for Female Infertility Treatment
Femasys Announces Partnership With Hrc Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer Femaseed
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
No comment yet